期刊
出版社
MEDYCYNA PRAKTYCZNA SP K SP ZOO
DOI: 10.20452/pamw.16230
关键词
-
The Polish Society of Epidemiologists and Infectiologists has updated their recommendations for the management of COVID-19, taking into account the ongoing pandemic, emergence of new variants, and availability of new drugs. The changes include the use of remedesivir in outpatient settings, addition of other antiviral drugs, revision of the use of monoclonal antibodies, and increased recommended dose of glucocorticosteroids for severe cases.
The first Polish recommendations regarding the management of patients with COVID-19 were published by the Polish Society of Epidemiologists and Infectiologists (PTEiLChZ) on March 31, 2020, and the last annex was dated November 12, 2021. The ongoing state of pandemic, the emergence of new variants of the virus, and the availability of new drugs necessitate their updating. Changes introduced in the current version of recommendations for the management of COVID-19 comprised the possibility of using remedesivir in an outpatient setting, previously reserved for inpatient treatment, as well as other antiviral drugs-molnupiravir and nirmatrelvir/ritonavir. We revised the possibility of using monoclonal antibodies due to the resistance of the currently dominant Omicron variant. Anakinra, an antagonist of interleukin 1 receptors, has been added as a treatment option in advanced stages of the disease, and the recommended daily dose of glucocorticosteroids used in the most severe forms of COVID-19 has been increased. Information on vaccination and pre-exposure prophylaxis in specific populations has also been updated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据